about
In memoriam--Richard M. Elliott (1954-2015)Recent developments in human immunodeficiency virus-1 latency researchSelective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispeciesFeline herpesvirus infection. ABCD guidelines on prevention and managementUse of CD134 as a primary receptor by the feline immunodeficiency virus.Feline panleukopenia. ABCD guidelines on prevention and management.Feline immunodeficiency virus (FIV) env recombinants are common in natural infections.Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence.Expression of CXCR4 on feline peripheral blood mononuclear cells: effect of feline immunodeficiency virus infection.Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus.The role of BST2/tetherin in feline retrovirus infectionFeline immunodeficiency. ABCD guidelines on prevention and management.Mapping the domains of CD134 as a functional receptor for feline immunodeficiency virus.Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection.Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccineContrasting clinical outcomes in two cohorts of cats naturally infected with feline immunodeficiency virus (FIV).An investigation of the breadth of neutralizing antibody response in cats naturally infected with feline immunodeficiency virusRapid evolution of the env gene leader sequence in cats naturally infected with feline immunodeficiency virus.Feline immunodeficiency virus (FIV) neutralization: a reviewEfficient generation of vesicular stomatitis virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and their use in quantifying virus neutralising antibodies.Feline immunodeficiency virus in South America.Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligandEnhanced immunosurveillance for animal morbilliviruses using vesicular stomatitis virus (VSV) pseudotypesAbility of vaccine strain induced antibodies to neutralize field isolates of caliciviruses from Swedish cats.Chemokine receptors and co-stimulatory molecules: unravelling feline immunodeficiency virus infection.A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction.Genetically divergent strains of feline immunodeficiency virus from the domestic cat (Felis catus) and the African lion (Panthera leo) share usage of CD134 and CXCR4 as entry receptors.Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus.Truncation of TRIM5 in the Feliformia explains the absence of retroviral restriction in cells of the domestic catFeline leukaemia. ABCD guidelines on prevention and management.Feline rabies. ABCD guidelines on prevention and management.Feline infectious peritonitis. ABCD guidelines on prevention and management.Chlamydophila felis infection. ABCD guidelines on prevention and management.Bordetella bronchiseptica infection in cats. ABCD guidelines on prevention and management.H5N1 avian influenza in cats. ABCD guidelines on prevention and management.Restriction of the felid lentiviruses by a synthetic feline TRIM5-CypA fusion.Feline leukaemia virus: half a century since its discovery.Aujeszky's disease/pseudorabies in cats: ABCD guidelines on prevention and management.Bartonella species infection in cats: ABCD guidelines on prevention and management.Pasteurella multocida infection in cats: ABCD guidelines on prevention and management.
P50
Q26700157-A0EF8398-0D4D-4E82-9589-1106E2150CCAQ27013114-2A41C4F6-8C6E-4747-B7F4-BD4EC5F84F10Q27318192-E551D1C5-F4F8-4DC0-A3EC-C801A72614FAQ30053613-6EF0867E-1F18-43A8-9BAF-22C8BDA9E226Q33198495-66851D4B-A0BF-4F08-9355-3098CD752783Q33384714-C748ACC0-B311-4A81-9764-B12630335B7AQ34270843-0D10D125-DB91-4970-A1BC-C6E1465C7D93Q34339634-ED48A137-F8FA-4820-96A5-1C8BD45C3665Q34461442-959A3158-814D-4AC0-BB0C-DA00FDD296DAQ34545719-D6851AD0-DCBB-4C8F-9D45-319DC1E537AEQ34664616-6F5E5830-649B-4731-BEE9-A5D8E8109883Q34983862-6350F0E0-6287-41B3-BC10-000852FD35CCQ35023787-A952B407-5762-4617-82AC-21442FE3C590Q35076983-EF215A9C-95FD-42AB-BF98-0267B6746BB8Q35082956-762CD0AB-7304-4B64-8A07-364678230DA7Q35095616-F74D8BE9-31D2-43FE-9056-1BDCFE7F81E5Q35109028-6F2D91B9-CC57-40D2-B785-1BC453FB6B99Q35182754-09FE08E5-A5CE-4773-B13E-8BF03CF893CBQ35491705-151809B6-FA0F-4FDA-880C-8CFCAC95A37DQ35878839-231E45EB-596E-4CAA-A51C-19083DCBD6C3Q35942681-EF1D038A-E288-445F-BB07-4F9C7E9C6ADEQ36098854-88156878-E4D1-4F00-AB9A-079C30CAA347Q36164148-B1A77421-EA0D-437E-9FB4-5B2F64894864Q36365997-2AA1990D-449B-43EB-9475-598F3E0D7BF3Q36699711-E11D59F6-4814-4F09-ABC4-A301D5E928E0Q36926701-32115748-907F-40E9-8230-F54656242919Q36949588-B099EF20-AB60-417C-8FA5-36AF002ECABCQ37177498-98771CA8-E472-472A-99D5-4CCCD7D65FCDQ37275106-E1D6F215-8C31-4F62-BDED-C1E79BD72F71Q37500845-FCE629C7-A10E-4217-96DA-EB24E6254B15Q37500852-3426758D-BD80-4C9F-8E7F-94D6DC633D18Q37500857-8A6BBF47-D247-4C80-A1D4-9192AFE7C91CQ37500862-CE0B1E3C-8B58-4C1C-BBEA-DC62EDABDB24Q37500866-12D536A4-7B60-4CEE-8725-A2290C7E1104Q37500872-DAE3293A-6751-458D-B7D7-5350D0F18736Q37911028-43A254F6-3E66-4271-ADB9-51465A50CFAAQ38032360-01623739-05B4-44BC-A995-5A9742711EE6Q38118250-9AE8E479-03F8-4DD9-87AA-BDFE6D0D776DQ38118251-278932A9-D533-4485-BB01-748B09F235D1Q38118252-CDD1A8EE-A574-4192-9807-20705AC1227C
P50
description
researcher
@en
name
Margaret J Hosie
@en
type
label
Margaret J Hosie
@en
prefLabel
Margaret J Hosie
@en